Bavarian will market Covid-19 vaccine on its own – but doesn't rule out future partners

In the past, the biotech firm has very publicly stated that partnerships are the way forward regarding its RSV candidate – but when it comes to the firm’s Covid-19 efforts, cards have been kept closer to the chest.
Paul Chaplin, CEO of Bavarian Nordic | Photo: Bavarian Nordic /PR
Paul Chaplin, CEO of Bavarian Nordic | Photo: Bavarian Nordic /PR
by christian bundgaard, translated by daniel pedersen

There’s no shortage of competition on the Covid-19 vaccine market, and things aren’t made easier for Danish biotech firm Bavarian Nordic by competitors being some of the biggest players in the world – remaining so even after a year and some time since the first vaccines against Covid-19 hit the market.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading